BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37511335)

  • 1. Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells.
    Chen L; Luo J; Zhang J; Wang S; Sun Y; Liu Q; Cheng C
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
    Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
    Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Therapeutic siRNA Nanoparticle Designed for Dual-Targeting CD44 and Gli1 of Gastric Cancer Stem Cells.
    Yao H; Sun L; Li J; Zhou X; Li R; Shao R; Zhang Y; Li L
    Int J Nanomedicine; 2020; 15():7013-7034. PubMed ID: 33061365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction sensitive nanocarriers mPEG-g-γ-PGA/SSBPEI@siRNA for effective targeted delivery of survivin siRNA against NSCLC.
    Chen L; Wang S; Liu Q; Zhang Z; Lin S; Zheng Q; Cheng M; Li Y; Cheng C
    Colloids Surf B Biointerfaces; 2020 Sep; 193():111105. PubMed ID: 32417465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment.
    Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H
    Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin.
    Zou S; Cao N; Cheng D; Zheng R; Wang J; Zhu K; Shuai X
    Int J Nanomedicine; 2012; 7():3823-35. PubMed ID: 22888237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.
    Sun M; Yang C; Zheng J; Wang M; Chen M; Le DQS; Kjems J; Bünger CE
    Acta Biomater; 2015 Dec; 28():171-182. PubMed ID: 26415776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
    Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
    Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
    ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
    Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
    Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
    Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
    Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
    Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR
    Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine-Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin.
    Cao Y; Huang HY; Chen LQ; Du HH; Cui JH; Zhang LW; Lee BJ; Cao QR
    ACS Appl Mater Interfaces; 2019 Mar; 11(10):9763-9776. PubMed ID: 30776886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor microenvironment dual-responsive core-shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA.
    Wang T; Yu X; Han L; Liu T; Liu Y; Zhang N
    Int J Nanomedicine; 2017; 12():4773-4788. PubMed ID: 28740384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
    Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
    Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
    Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
    Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.